SCHEMBL384147

SCHEMBL384147

O=C(Cl)CCCCC1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 3/20 0.50
PHF8 Q9UPP1 3/20 0.50
KDM2A Q9Y2K7 3/20 0.50
KDM4C Q9H3R0 2/20 0.50
KDM4A O75164 1/20 0.50
SIGMAR1 Q99720 3/20 0.47
NAAA Q02083 2/20 0.46
CYP1A2 P05177 1/20 0.45
EPHX1 P07099 1/20 0.45
HPGD P15428 1/20 0.44
GLA P06280 2/20 0.43
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9061840 0.98 KDM5A (0.53) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL19612642 0.98 KDM5A (0.53) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL9089300 0.98 KDM5A (0.53) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL6521504 0.96 KDM5A (0.51) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL6519311 0.96 KDM5A (0.51) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL1283873 0.94 CYP1A2 (0.46) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL8788705 0.91 CYP1A2 (0.43) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL25192919 0.90 CYP1A2 (0.43) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL11654522 0.89 KDM5A (0.46) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL11845113 0.87 KDM5A (0.49) KDM5APHF8KDM2AKDM4CKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592738-B1 RESIN COMPOSITIONS CIBA HOLDING INC (CH) 2020-07-29 EP disclosed
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-7790793-B2 Amide nucleating agent compositions CIBA SPECIALTY CHEM. CORP. (US) 2010-09-07 US disclosed
WO-2010098119-A1 COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE COMPLEX COMPOUND 三井化学株式会社 (JP) 2010-09-02 WO disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
CN-100406437-C Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing them SANKYO CO (JP) 2008-07-30 CN disclosed
US-6177438-B1 ANALGESICS, DIURETICS, ANTITUSSIVE AGENTS TORAY INDUSTRIES, INC. (JP) 2001-01-23 US disclosed
US-6147084-A Brain cell protective agent TORAY INDUSTRIES, INC. (JP) 2000-11-14 US disclosed
WO-1999059959-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ASTRAZENECA AB (SE) 1999-11-25 WO disclosed
US-5972953-A MORPHINAN DERIVATIVE; USEFAL AS PREVENTIVE AND THERAPUETIC AGENTS OF ISCHEMIC BRAIN DISORDERS, BRAIN NERVE CELL DISORDERS AND DEMENTIA TORAY INDUSTRIES, LTD. (JP) 1999-10-26 US disclosed
EP-0661283-B1 BRAIN CELL PROTECTIVE TORAY INDUSTRIES (JP) 1998-10-21 EP disclosed
US-5486526-A APPETITE SUPPRESSANTS THE UNIVERSITY OF TOLEDO (US) 1996-01-23 US disclosed
EP-0663401-A1 MORPHINAN DERIVATIVE AND MEDICINAL USE TORAY INDUSTRIES, INC. (JP) 1995-07-19 EP disclosed
EP-0661283-A1 BRAIN CELL PROTECTIVE TORAY INDUSTRIES, INC. (JP) 1995-07-05 EP disclosed
EP-0633883-A1 PROCESS FOR THE PREPARATION OF 4-PYRIDYL- AND 4-PIPERIDINYLIMIDAZOLES USEFUL AS INTERMEDIATES FOR THE SYNTHESIS OF HISTAMINE RECEPTOR ANTAGONISTS THE UNIVERSITY OF TOLEDO (US) 1995-01-18 EP disclosed
WO-1993020062-A1 PROCESS FOR THE PREPARATION OF 4-PYRIDYL- AND 4-PIPERIDINYLIMIDAZOLES USEFUL AS INTERMEDIATES FOR THE SYNTHESIS OF HISTAMINE RECEPTOR ANTAGONISTS THE UNIVERSITY OF TOLEDO (US) 1993-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 KDM5A 1556/4885PHF8 910/4885KDM2A 1403/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A KDM5A 2461/4885PHF8 1261/4885KDM2A 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.